Retatrutide Side Effects: What the Phase 2 Data Shows

What Are the Side Effects of Retatrutide?

Most retatrutide side effects are stomach problems. Nausea, diarrhoea, vomiting and constipation account for the bulk of reports across Phase 2 and Phase 3 trials. They are dose dependent and cluster in the weeks when the dose is raised. Dysesthesia, an odd skin sensation, appears mainly at the highest doses. Serious events stayed rare.

Everything below comes from published trial data, not from anecdote. If you are researching this compound, our sources page gives a vendor-neutral rundown. This content is for educational purposes only, the compounds are intended for research use, and none of it replaces a conversation with your own clinician.

Retatrutide Side Effects in the Gut: How Common Are They?

Stomach symptoms are the largest single category. At higher doses they hit roughly a third to just under half of trial participants. They tend to fade once the dose is stable, rather than continuing for the whole treatment.

The Phase 2 obesity trial recorded them as the most frequent adverse events. They were mostly mild to moderate, and they came mainly during dose escalation. The same trial recorded a 24.2% mean weight reduction at 12 mg, against 2.1% on placebo at 48 weeks. Jastreboff 2023

A Phase 2 trial in people with type 2 diabetes found a similar pattern. Nausea, diarrhoea, vomiting and constipation affected 35% of people taking retatrutide, compared with 13% on placebo. In the group given a fast 8 mg dose increase, that number rose to as high as 50%. Rosenstock 2023

A 2025 meta-analysis combined several trials and confirmed a clear pattern: higher doses cause more side effects. The 4 mg dose did not raise side effects much more than placebo. But the 12 mg dose raised the risk of any side effect by 1.34 times compared with placebo. Abdrabou 2025

The larger Phase 3 TRIUMPH-1 programme put numbers on each symptom across the 4 to 12 mg doses. Nausea ranged from 28.6% to 42.4%, against 14.8% on placebo. Diarrhoea ran 25.2% to 32.0%, against 13.5%. Vomiting reached 10.6% to 25.3%, against 4.8%. None of that means the drug is poorly tolerated. It means the burden scales with dose, the way most incretin therapies do.

Dysesthesia: One of the Retatrutide Side Effects Unique to This Drug

Dysesthesia is an odd skin sensation. People describe it as tingling, prickling, or skin that feels different to the touch. It is the one side effect that sets retatrutide apart from semaglutide and tirzepatide. It appeared in roughly 1 in 5 participants at the 12 mg dose in Phase 3. It was not prominent in the earlier Phase 2 data, and it appears linked to the drug's added glucagon receptor activity.

Extended TRIUMPH-1 data ran to 104 weeks. It put dysesthesia and urinary tract infections at around one in ten patients on the highest doses. Both were generally mild to moderate. Most resolved during treatment rather than forcing anyone to stop.

This is a genuinely new signal in the triple-agonist class. It is separate from the stomach pattern that retatrutide shares with older GLP-1 drugs. It is the one to flag if you notice unusual skin sensations after a dose increase.

Retatrutide Side Effects on Heart Rate

Retatrutide does raise resting heart rate, modestly, and the rise reverses. It typically goes up by 5 to 10 beats per minute. The size of the rise tracks the dose. It peaks around week 24 and falls from there.

No major adverse cardiovascular events have been reported in the published trials. The mechanism sits with the drug's glucagon receptor component, not with the GLP-1 or GIP pathways.

The Phase 2 obesity trial that produced the weight-loss headline tracked this signal alongside the main endpoint. The pattern held across dose groups without turning into serious cardiac events. Jastreboff 2023

Already carry a cardiovascular risk factor? Raise the heart rate shift with a clinician. Do not assume it settles on its own.

Is Retatrutide Safe? What the Serious Events Show

Serious adverse events have tracked at rates close to placebo, at around 4% in each arm of Phase 2. That is the strongest evidence available that the rare serious events reported were not clearly caused by the drug. Three risks are worth understanding on their own terms rather than as one lump: pancreatitis, thyroid tumours and gallbladder disease.

One case of acute pancreatitis occurred at the 12 mg dose in Phase 2. Other participants showed raised amylase and lipase without ever developing pancreatic symptoms.

A related Phase 2a substudy looked at people with metabolic dysfunction-associated steatotic liver disease. This means fat has built up in the liver. Liver fat dropped by 22.8% at the 8 mg dose and 24.2% at the 12 mg dose, over 48 weeks. But bigger benefits came with more need for monitoring. Sanyal 2024

Retatrutide Side Effects: Cancer Risk Explained

Thyroid C-cell tumours are a class-wide concern. The concern originates in rodent studies of GLP-1 agonists, not in human data.

No human case of medullary thyroid carcinoma (a rare thyroid cancer) has been reported in any retatrutide trial. Nor has C-cell hyperplasia, the tissue change that can come before it. That is where the evidence stands. It is why the do-not-use rule below is built on family history, not on cases seen in trials.

Gallbladder events, meaning gallstones and cholecystitis, occurred at low rates comparable to placebo. Rapid weight loss is itself a risk factor for gallstones, whichever drug drove the loss.

What the Retatrutide Side Effects Clinical Trials Show About Dose Escalation

Trial doses ran from 0.5 mg up to 12 mg once weekly. The biggest thing separating people who tolerate treatment from people who stop early is not the final dose. It is how fast the dose was raised.

Skipping planned titration steps has been linked to roughly double the stomach symptom rate, compared with a gradual schedule.

Discontinuation because of adverse events ran 7% to 9% in Phase 2. It climbed to 12% to 18% in the longer Phase 3 trials. The 12 mg arm of TRIUMPH-1 showed 11.3% discontinuation, against 4.9% on placebo. That gap narrows a lot at lower, slower-titrated doses. Always work with a qualified clinician before changing your protocol, and especially before changing how fast a dose goes up.

Who Should Not Take Retatrutide?

Doctors should not give retatrutide to people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer). The same rule applies to people with Multiple Endocrine Neoplasia type 2 (a genetic disorder that raises tumour risk). It also applies to people with severe kidney problems or uncontrolled thyroid disease.

Take extra care if you have a history of pancreatitis, gallbladder disease, or severe gut disease. That includes gastroparesis, where the stomach empties too slowly.

Before starting retatrutide, doctors usually run baseline blood tests. These check TSH and free T4 (thyroid hormones), amylase and lipase (pancreas enzymes), liver enzymes, and kidney function. These results give a starting point to compare against if symptoms show up later. But blood tests alone are not enough. A full medical history review with a qualified doctor still matters, especially given how side effects increase with higher doses.

Retatrutide Peptide Side Effects vs Semaglutide and Tirzepatide

On stomach symptoms, retatrutide sits close to both. Its added glucagon receptor activity brings two effects the older drugs do not match. One is the dysesthesia signal. The other is a sharper dose-dependent rise in heart rate.

A separate study asked Phase 2 participants about their experience, adding detail that percentage tables miss. Out of 36 people taking retatrutide, 31 said it improved their lifestyle. Two people said they became less social or did less leisure activity. They linked this to side effects or to new eating habits. Goetz 2025

Another study pooled data from three trials with 640 people in total. This type of study is called a meta-analysis, meaning it combines results from several trials into one. It found that retatrutide caused more mild side effects than placebo. These included gut problems and hypersensitivity reactions (allergy-type reactions). The study also confirmed an average weight loss of 10.66 kg. Pasqualotto 2024

Before you track any of these effects, it helps to know what you are actually holding. Our guide on how to know if peptides are real covers that sourcing question.

References

• Jastreboff et al. 2023, New England Journal of Medicine. NEJMoa2301972
• Rosenstock et al. 2023, PubMed. 37385280
• Abdrabou et al. 2025, PMC. PMC12026077
• Pasqualotto et al. 2024, PMC. PMC11420505
• Sanyal et al. 2024, PubMed. 38858523
• Goetz et al. 2025, PubMed. 41216380

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.